Last edition
News about "Concord Biotech global footprint"
Concord Biotech Successfully Completes ANVISA Inspection at Limbasi API Manufacturing Facility
Concord Biotech has successfully completed an ANVISA inspection at its Limbasi Active Pharmaceutical Ingredient (API) manufacturing facility, strengthening its regulatory standing and expansion into Brazil's pharmaceutical market.
Concord Biotech Global Footprint | 12/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members